Our study of 3877 mutation carriers with 426 incident breast cancer cases is the largest prospective cohort to date and the first prospective study investigating breast cancer risk after RRSO for BRCA1 and BRCA2 mutation carriers in the context of menopausal status. This evidence concerns the gene BRCA2 and breast carcinoma.